Lupus & antiphospholipid syndrome
Long-term steroid-sparing effect of belimumab in systemic lupus erythematosus: Post hoc pooled analysis of OBSErve multi-country cohort data
Authors' conclusion
These results from a real-world clinical setting suggest that belimumab treatment supports patients in achieving EULAR-recommended OGC taper goals, with sustained OGC dose reductions observed alongside an increased percentage of patients attaining low disease activity and remission as early as 6 months following belimumab initiation.
Study context
- Population
- Adults with systemic lupus erythematosus (SLE) initiating belimumab in OBSErve studies, eight countries (6–24 months data from USA and Argentina)52.2% from the USA
- Participants
- 959 adults
- Outcome
- Patients prescribed OGC at index receiving ≤5 mg/day OGC
- Follow-up
- 6 and 24 months post-initiation
Methodological detailsdescriptive, pooled data, eight countries, real-world, Sample size fixed by available data from the OBSErve studies
- Descriptive
- Pooled data
- Eight countries
- Real-world
- Sample size fixed by available data from the OBSErve studies
Pooled result
As reported in the abstract
- Receiving ≤5 mg/day oral glucocorticoid (OGC) at belimumab initiation
- 16.1%
- Receiving ≤5 mg/day OGC at 6 months
- 51.6%
- Receiving ≤5 mg/day OGC at 24 months
- 87.5%
- Discontinued OGC at 6 months
- 8.2%
- Discontinued OGC at 24 months
- 44.4%
Original publication
Long-term steroid-sparing effect of belimumab in systemic lupus erythematosus: Post hoc pooled analysis of OBSErve multi-country cohort data. Lupus. Published 2 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →